BPC-157 Hamstring Clinical Trial: Phase 2 Study Explained
NCT07437547 is a randomised, placebo-controlled Phase 2 trial testing whether BPC-157 speeds up recovery from an acute hamstring strain. It plans to enrol 120 adults and is currently recruiting, so there are no results yet. If completed and published, it would be the strongest human test of BPC-157 to date.
Trial at a glance
Why does this trial matter?
This trial is designed to test BPC-157 against a placebo in humans, which would provide substantially stronger evidence than the small uncontrolled reports published so far. It is the first registered placebo-controlled efficacy trial of BPC-157 since the 2000s.
What is the trial testing?
Whether people with a moderate (grade II) hamstring tear who receive BPC-157 injections alongside standard rehabilitation recover faster than people who receive placebo injections alongside the same rehabilitation.
How is the trial designed?
Participants with a hamstring strain confirmed by MRI scan are randomly assigned to receive either BPC-157 or an identical-looking placebo, given by injection once daily for 14 days. Both groups follow the same standardised rehabilitation programme. Neither the participants nor the researchers know who is receiving which treatment until the trial ends.
What is the trial designed to measure?
- How quickly participants return to unrestricted sport: measured in days.
- The change in injury size on MRI scans at day 14: assessed by radiologists who do not know which treatment each participant received.
Are results available yet?
No. The trial began recruiting in Shenzhen, China in February 2026 and lists an estimated completion of February 2028. No results have been posted.
What can be concluded now?
Nothing about whether BPC-157 works. A trial in progress is research activity, not evidence of an outcome. What the registration does show is that a placebo-controlled human test of BPC-157 is finally underway.
What this trial does not prove
- Registration does not prove the trial will be completed or published.
- It does not prove BPC-157 is safe.
- It does not prove BPC-157 works.
- An ongoing trial has no outcome yet.
Evidence strength
Research compound studied
BPC-157
This trial investigates BPC-157, a synthetic peptide of 15 amino acids. Batch-tested BPC-157 with certificates of analysis is available from our catalogue.
Sold for laboratory research use only. Not for human consumption. Nothing on this page is a claim that any product treats or prevents any condition.
How does this fit with other BPC-157 human research?
The full published human evidence is currently limited to three small uncontrolled reports. This trial, if completed and published, would sit two rungs higher on the evidence ladder. Separately, athletes should note that BPC-157 is banned in competitive sport under the WADA Prohibited List. View all BPC-157 clinical trials and human studies →
Primary registry record
Hudson Biotech. A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Pentadecapeptide BPC 157 for Accelerated Repair of Acute Grade II Hamstring Strain Confirmed by MRI. ClinicalTrials.gov identifier NCT07437547. First posted 27 February 2026.
View the ClinicalTrials.gov record →